Daiichi Sankyo Co., Ltd., Japan Vaccine Co., Ltd. and Sanofi K.K. announced that they will launch "Squarekids subcutaneous injection syringe", a 4-tetravalent combination vaccine (DPT-IPV) for the prevention of diphtheria, pertussis, tetanus and poliomyelitis (polio) on December 9, 2015.
The U.S. Food and Drug Administration approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer. Portrazza is marketed by Eli Lilly and Company, based in Indianapolis, Indiana.